To include your compound in the COVID-19 Resource Center, submit it here.

Mologen's lefitolimod misses in extension for HIV infection

Mologen AG (Xetra:MGN) reported data from 12 patients with chronic HIV-1 infection on antiretroviral therapy (ART) in a 24-week extension of the open-label, Danish Phase Ib/IIa TEACH trial showing that twice-weekly 60 mg

Read the full 334 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE